Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ALK-Abello and Torii Pharmaceutical have signed a licensing agreement for the development and commercialization of house dust mite allergy immunotherapy products for the treatment of asthma and allergic rhinitis in Japan.
Subscribe to our email newsletter
The tie up licenses Torlii Pharma for the development, marketing and distribution of Mitizax, ALK’s tablet which is indicated for the treatment of house dust allergy.
As per the terms of the agreement, Torlii Pharma is responsible to pay an upfront payment of EUR30m and EUR30m as the development and marketing registration milestone to ALK.
Torlii Pharma is also responsible to pay royalty payments and sales milestones on the net sales of the products.
Torii Pharma president Norihiko Matsuo said Torii is currently conducting a Phase III clinical study of a liquid, sublingual immunotherapy product for Japanese cedar pollen allergy.